PropertyValue
?:definition
  • A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes derived from cancer-testis antigens with potential immunostimulatory and antitumor activities. The peptide epitopes are derived from up-regulated lung cancer 10 (URLC10); cell division cycle associated 1 (CDCA1); and kinesin-like family member 20A (KIF20A). Upon administration, HLA-A*2402-restricted URLC10-CDCA1-KIF20A multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URL10-, CDCA1-, and KIF20A-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for \'https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C90566\' active clinical trials using this agent. (\'http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C90566\' NCI Thesaurus)
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
expand all